BC Week In Review | Apr 6, 2018
Financial News

ALS newco QurAlis launches

Amyotrophic lateral sclerosis company QurAlis Corp. (Cambridge, Mass.) debuted with seed funding from MP Healthcare Venture Management, Amgen Ventures and Alexandria Venture Investments. QurAlis CEO Kasper Roet declined to disclose financial terms. QurAlis is targeting...
BC Extra | Apr 5, 2018
Financial News

ALS newco QurAlis launches

Amyotrophic lateral sclerosis company QurAlis Corp. (Cambridge, Mass.) debuted with seed funding from MP Healthcare Venture Management, Amgen Ventures and Alexandria Venture Investments. QurAlis CEO Kasper Roet declined to disclose financial terms. QurAlis is targeting...
BC Innovations | Jun 9, 2016
Distillery Therapeutics

Therapeutics: Potassium channel Kv7.3 (KCNQ3)

Neurology INDICATION: Depression Mouse studies suggest promoting KCNQ3 expression or opening potassium channels could help treat major depressive disorder (MDD). In a mouse model of chronic depression, expression of KCNQ3 in ventral tegmental area dopaminergic...
BC Week In Review | Jul 13, 2015
Clinical News

SciFluor preclinical data

In rodents, SF0034 was “a more potent and less toxic” anticonvulsant than Trobalt retigabine. Additionally, SF0034 prevented the development of tinnitus in mice. Data were published in The Journal of Neuroscience. SF0034 is a potassium...
BC Extra | Apr 23, 2015
Financial News

SciFluor raises $30M in series A

Allied Minds plc (LSE:ALM) subsidiary SciFluor Life Sciences LLC (Cambridge, Mass.) raised $30 million in an untranched series A round led by new investors Invesco Asset Management and Woodford Investment Management. Allied Minds and affiliated...
BC Innovations | Sep 4, 2014
Strategy

Meeting of the minds

Since its inception in 2006, Allied Minds plc has primarily invested in and incubated early stage research from U.S. academic institutions and federal labs, with a focus on medical devices and healthcare information technology. Now...
BC Innovations | Jun 27, 2013
Distillery Therapeutics

Indication: Other

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Other Tinnitus Potassium channel Kv7.2 (KCNQ2); KCNQ3 Mouse and cell culture studies suggest improving the activity of KCNQ2 and KCNQ3 could help...
Items per page:
1 - 7 of 7